A Phase I Dose Escalation Study of NKP-1339 Administered on Days 1, 8 and 15 of Each 28-Day Cycle in Patients With Advanced Solid Tumors Refractory to Treatment.
Phase of Trial: Phase I
Latest Information Update: 20 May 2017
At a glance
- Drugs IT 139 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Niiki Pharma
- 19 Jun 2013 Status changed from active, no longer recruiting to completed, based on information in an Intezyne Technologies media release.
- 02 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Jan 2012 Interim results of the first 30 patients evaluable for dose determination have been presented in a media release from Niiki Pharma.